Srikripa Devarakonda Analyst PerformanceBiotech Equity Analyst at Truist FinancialSrikripa Devarakonda is a stock analyst at Truist Financial focused in the medical sector, covering 18 publicly traded companies. Over the past year, Srikripa Devarakonda has issued 39 stock ratings, including strong buy, buy, and hold recommendations. While full access to Srikripa Devarakonda's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Srikripa Devarakonda's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings47 Last 4 YearsBuy Recommendations80.49% 33 Buy RatingsCompanies Covered18 Unique Companies Ratings Distribution41RatingsDistribution of strong buy, buy, hold, and sell ratings by Srikripa Devarakonda.RatingPercentageCount Strong Buy2.4%1 ratings Buy78.0%32 ratings Hold19.5%8 ratings Sell0.0%0 ratingsOut of 41 total stock ratings issued by Srikripa Devarakonda at Truist Financial, the majority (78.0%) have been Buy recommendations, followed by 19.5% Hold and 2.4% Strong Buy.Best & Worst CallsBest Call000.0%BIIBApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%INCYOct 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ83.3% of companies on NASDAQ15 companiesNYSE16.7% of companies on NYSE3 companiesSrikripa Devarakonda, an analyst at Truist Financial, currently covers 18 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical17 companies94.4%Manufacturing1 company5.6%Srikripa Devarakonda of Truist Financial specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies72.2%LARGE CAP PHARMA2 companies11.1%PHARMACEUTICAL PREPARATIONS1 company5.6%MED - DRUGS1 company5.6%MEDICAL SERVICES1 company5.6% Srikripa Devarakonda's Ratings History at Truist Financial Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsPTGXProtagonist Therapeutics4/14/2026Boost Price Target$104.28$121.00Buy$0.0000.00% ROIBIIBBiogen4/13/2026Lower Price Target$173.49$189.00Hold$0.0000.00% ROITERNTerns Pharmaceuticals3/31/2026Downgrade$52.81$53.00Hold$0.0000.00% ROIIVAInventiva3/19/2026Initiated Coverage$5.96$13.00Buy$0.0000.00% ROIARVNArvinas3/18/2026Set Price Target$10.95$10.00$0.0000.00% ROIIVAInventiva3/18/2026Upgrade$6.04Strong-Buy$0.0000.00% ROISEPNSepterna3/11/2026Boost Price Target$27.69$35.00Buy$0.0000.00% ROIMBXMBX Biosciences3/9/2026Set Price Target$28.85$50.00$0.0000.00% ROISRRKScholar Rock3/3/2026Boost Price Target$44.31$55.00Buy$0.0000.00% ROIBIIBBiogen2/9/2026Boost Price Target$201.18$193.00Hold$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CYTKCytokinetics2/3/2026Boost Price Target$65.16$92.00Buy$0.0000.00% ROIBIIBBiogen1/8/2026Boost Price Target$185.65$190.00Hold$0.0000.00% ROIPTGXProtagonist Therapeutics1/5/2026Boost Price Target$87.18$110.00Buy$0.0000.00% ROIINCYIncyte12/24/2025Set Price Target$100.91$103.00$0.0000.00% ROICYTKCytokinetics12/22/2025Set Price Target$67.47$84.00$0.0000.00% ROISEPNSepterna12/15/2025Initiated Coverage$25.44$34.00Buy$0.0000.00% ROISEPNSepterna12/15/2025Initiated Coverage$26.23$34.00Buy$0.0000.00% ROIKYMRKymera Therapeutics12/9/2025Boost Price Target$87.24$116.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals12/9/2025Boost Price Target$40.23$56.00Buy$0.0000.00% ROIBMYBristol Myers Squibb12/3/2025Set Price Target$50.97$65.00$0.0000.00% ROIKYMRKymera Therapeutics11/26/2025Boost Price Target$67.24$80.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals11/24/2025Initiated Coverage$767.36$798.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals11/19/2025Boost Price Target$26.89$35.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/19/2025Boost Price Target$557.95$640.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals11/4/2025Reiterated Rating$14.03$28.00Buy$0.0000.00% ROIINCYIncyte10/29/2025Reiterated Rating$90.30$93.00Hold$0.0000.00% ROIPTGXProtagonist Therapeutics10/28/2025Boost Price Target$76.39$88.00Buy$0.0000.00% ROISRRKScholar Rock10/20/2025Lower Price Target$28.09$44.00Buy$0.0000.00% ROIVTRSViatris10/15/2025Initiated Coverage$9.93$15.00Buy$0.0000.00% ROIMBXMBX Biosciences10/15/2025Initiated Coverage$13.52$50.00Buy$0.0000.00% ROIVTRSViatris10/15/2025Initiated Coverage$9.98$15.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals10/14/2025Initiated Coverage$437.10$580.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals10/14/2025Initiated Coverage$8.08$20.00Buy$0.0000.00% ROIKYMRKymera Therapeutics9/30/2025Boost Price Target$58.33$68.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals8/11/2025Lower Price Target$559.54$812.00Buy$0.0000.00% ROIINCYIncyte7/30/2025Boost Price Target$77.98$79.00Hold$0.0000.00% ROIINCYIncyte5/27/2025Boost Price Target$65.57$73.00Hold$0.0000.00% ROIARVNArvinas5/5/2025Reiterated Rating$7.72$11.00Hold$00.0000.00% ROIREGNRegeneron Pharmaceuticals4/30/2025Lower Price Target$592.47$940.00Buy$000.0000.00% ROIBIIBBiogen4/29/2025Lower Price Target$120.86$199.00Buy$000.0000.00% ROIREGNRegeneron Pharmaceuticals4/23/2025Lower Price Target$589.00$975.00Buy$000.0000.00% ROIKROSKeros Therapeutics4/9/2025Lower Price Target$9.76$25.00Buy$00.0000.00% ROIBIIBBiogen2/13/2025Lower Price Target$133.43$210.00Buy$000.0000.00% ROILLYEli Lilly and Company2/3/2025Boost Price Target$814.06$1,038.00Buy$0000.0000.00% ROIABBVAbbVie2/3/2025Boost Price Target$189.52$217.00Buy$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyRoyal Bank Of CanadaBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
